Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex expand ADME capabilities with the introduction of 8 additional transporter assays

Cyprotex PLC
("Cyprotex" or "the Company")
Cyprotex expand ADME capabilities with the introduction of 8 additional transporter assays

Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of eight additional drug transporter assays. Drug transporters are present in multiple cells and tissues within the body. They play a major role in drug or chemical disposition by either pumping molecules out of the cell (efflux) or into the cell (uptake). These processes influence drug or chemical plasma exposures and levels within tissues in the body, which in turn can affect efficacy or toxicity of the molecule.

In total, Cyprotex can now evaluate potential activity or inhibition of 19 different drug transporters. The new transporter assays being launched by Cyprotex evaluate transport by PEPT1, PEPT2, NTCP, OATP1A2, OATP2B1, OAT2, OAT4 and OCTN2. These transporters have important roles in peptide (prodrug) transport (PEPT1 and PEPT2), bile acid transport (NTCP), and organ-specific disposition of drugs or chemicals (OATP1A2, OATP2B1, OAT2, OAT4, and OCTN2). Prior to this launch, Cyprotex already offered a full panel of transporter assays for regulatory drug-drug interaction studies to assess transport by P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K and BSEP. The additional transporters now being introduced allow Cyprotex to expand into more specialised transporter studies where drug delivery or organ-specific toxicity might be the primary investigation.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “Drug transporters influence all areas of our business including plasma/tissue concentrations and drug-drug interactions (ADME/PK), adverse effects in specific tissues/organs (Toxicity) and drug efficacy/therapeutic effect (Biosciences). Furthermore, expression of these transporters can vary in certain sub-populations and this can lead to unexpected toxicity or lack of efficacy in specific individuals. Therefore, understanding the role of transporters in drug or chemical disposition in the body is vitally important in extrapolating in vitro science to the patient situation.’

For Further Information

Cyprotex PLC 
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
ir@cyprotex.com
www.cyprotex.com

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
shaun.dobson@n1singer.com
Jen Boorer
jennifer.boorer@n1singer.com
www.nplus1singer.com

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™, chemTarget and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close